Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer.
about
Masked Chimeric Antigen Receptor for Tumor-Specific Activation.Spontaneous Post-Transplant Disorders in NOD.Cg- Prkdcscid Il2rgtm1Sug/JicTac (NOG) Mice Engrafted with Patient-Derived Metastatic Melanomas.Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015.Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinomaChallenges and opportunities of allogeneic donor-derived CAR T cellsBlockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells.CCR7+ selected gene-modified T cells maintain a central memory phenotype and display enhanced persistence in peripheral blood in vivo.CAR T-cell therapy: toxicity and the relevance of preclinical models.Exploiting cytokines in adoptive T-cell therapy of cancer.Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf.Lym-1 Chimeric Antigen Receptor T Cells Exhibit Potent Anti-Tumor Effects against B-Cell Lymphoma.CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity.HIV replication and latency in a humanized NSG mouse model during suppressive oral combinational ART.Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.T-cell Immunotherapies and the Role of Nonclinical Assessment: The Balance between Efficacy and Pathology.Genetically enhanced T lymphocytes and the intensive care unit.Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting
P2860
Q34047878-6B5A6CE4-5BFB-479F-BD11-4C61A5AF9BC0Q35634016-1F8E8161-49CF-423B-B376-F323CCCDA27FQ35641721-71091809-F00D-4122-832D-FBF469F4C1F1Q35677962-668C5EDD-CEE7-4411-8505-DAC5A6027570Q36257036-B7D8A524-1AA2-4888-9F9B-297A39BDBC6FQ36471557-F345D832-F267-4EF7-AE59-4D356F3407B1Q37603527-21EF72F5-5F17-4E4E-A8F2-8C03A6B51553Q37655544-8411EA74-6C8B-4DE8-9397-598B7593A0D8Q38525018-764B023C-2E00-4168-B5E3-0EA8147E593FQ38525044-B1951057-A953-4098-8BFB-562CA551FF74Q47215994-97285EE8-6F29-44BA-9DEC-E995273AAE3CQ47271647-D05D8CBE-1D63-4C66-9880-0E90147D349BQ49722865-7C0A8CB1-08C2-40E8-B325-B8F65E2DA673Q49990061-4401956F-FC38-4AB5-9EEC-63FCB7507CC8Q50531950-41AB9352-6686-40F3-8861-5E46AEDC3F13Q52689465-2FC63C7F-356C-4BD9-B72C-C087E3B9C7FFQ55380614-2F0E5A4C-6211-4B2A-82F4-986DF0E43EBBQ57293724-F01BBF62-623A-475D-A90F-71561B4454AF
P2860
Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Potential limitations of the N ...... man T cell therapy for cancer.
@en
Potential limitations of the N ...... man T cell therapy for cancer.
@nl
type
label
Potential limitations of the N ...... man T cell therapy for cancer.
@en
Potential limitations of the N ...... man T cell therapy for cancer.
@nl
prefLabel
Potential limitations of the N ...... man T cell therapy for cancer.
@en
Potential limitations of the N ...... man T cell therapy for cancer.
@nl
P2093
P2860
P356
P1476
Potential limitations of the N ...... man T cell therapy for cancer.
@en
P2093
David E Gilham
Erik M Alcantar-Orozco
Hannah Gornall
Robert E Hawkins
Vania Baldan
P2860
P304
P356
10.1089/HGTB.2013.022
P577
2013-08-24T00:00:00Z